Assessing parameters and standardising biomarker detection in CLL

Kostas Stamatopoulos

Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece discusses detection and analysis of biomarkers to risk stratify chronic lymphocytic leukemia (CLL) patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. He specifically mentions detecting deletions on chromosome 17p and TP53 mutation which results in the disruption of p53, leading to aggressive CLL.

Share this video